Mission Statement, Vision, & Core Values of XTL Biopharmaceuticals Ltd. (XTLB)

Are you curious about what drives a biopharmaceutical company focused on autoimmune diseases? Understanding a company's mission, vision, and core values provides insight into its goals and how it operates. Let's delve into the guiding principles of XTL Biopharmaceuticals Ltd. (XTLB), a company with a $11 million market cap as of April 2, 2025, and trailing 12-month revenue of $162K as of September 30, 2024. What exactly does XTL Biopharmaceuticals aim to achieve, and what values underpin their efforts in the competitive biotech landscape?

XTL Biopharmaceuticals Ltd. (XTLB) An Overview of

XTL Biopharmaceuticals Ltd. (XTLB) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of pharmaceutical products for the treatment of autoimmune diseases. Founded in 1993 and headquartered in Israel, XTL Biopharmaceuticals has focused on innovative therapies to address unmet medical needs. The company's pipeline includes treatments for autoimmune and infectious diseases.

As of April 2025, specific recent sales figures are not available in the provided search results. For detailed information regarding XTL Biopharmaceuticals Ltd.'s history, ownership structure, mission, and operational details, you can visit: XTL Biopharmaceuticals Ltd. (XTLB): History, Ownership, Mission, How It Works & Makes Money.

Detailed financial performance data, including revenue from main product sales and growth in key markets, requires up-to-date financial reports. For the most accurate and current financial information, please consult XTL Biopharmaceuticals Ltd.'s official investor relations releases and SEC filings.

XTL Biopharmaceuticals Ltd. operates in the competitive biopharmaceutical industry, striving to develop and bring to market innovative treatments. To further understand the factors contributing to the company's success, consider the following aspects:

• Product Pipeline: The strength and potential of its drug candidates.
• Market Position: Its competitive standing within the biopharmaceutical landscape.
• Strategic Partnerships: Collaborations that enhance research, development, and commercialization efforts.
• Financial Stability: The company’s ability to fund ongoing operations and research.

XTL Biopharmaceuticals Ltd. (XTLB) Mission Statement

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) is dedicated to the acquisition and advancement of pharmaceutical products and late-stage pharmaceutical candidates. The company focuses on addressing unmet clinical needs, particularly in autoimmune diseases.

XTL Biopharmaceuticals Ltd. operates as a biopharmaceutical company, it is involved in the acquisition and development of pharmaceutical drugs, with a primary focus on treating autoimmune diseases. Their pipeline includes hCDR1 for systemic lupus erythematosus and recombinant human erythropoietin (rHuEPO) for multiple myeloma.

As of April 7, 2025, Noam Band was appointed as the new Chief Executive Officer of XTL Biopharmaceuticals Ltd., signaling a commitment to innovation and operational excellence.

XTL's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. hCDR1 has completed three clinical trials involving more than 400 patients.

The company's recombinant human erythropoietin (rHuEPO) is being developed to prolong the survival of patients with advanced multiple myeloma and improve their quality of life.

XTL Biopharmaceuticals Ltd. completed the acquisition of The Social Proxy on August 14, 2024. The Social Proxy is an AI web data company that develops a unique ethical, IP-based proxy and data extraction platform for AI & BI Applications at scale.

XTL Biopharmaceuticals Ltd. is traded on the NASDAQ Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).

Here are key points about XTL Biopharmaceuticals Ltd.:
• Focuses on acquiring and developing pharmaceutical products.
• Aims to treat unmet clinical needs.
• Has two product candidates in clinical development: hCDR1 and Recombinant Erythropoietin (rHuEPO).
• hCDR1 is for the treatment of Systemic Lupus Erythematosus (“SLE”).
• rHuEPO is for the prolongation of multiple myeloma (MM) advanced-stage patients' survival and improvement of their quality of life.

As of April 2025, XTL Biopharmaceuticals Ltd. has a narrow economic moat with a fair value of $1.60 and the price is $1.10 as of April 14, 2025.

XTL Biopharmaceuticals Ltd. had revenue of $162,000 for the trailing 12-month period as of September 30, 2024.

The company's enterprise value as of April 2025 (TTM) is $14.35 million. This represents a 34.34% change compared to the average of $10.68 million of the last 4 quarters.

For more insights into XTL Biopharmaceuticals Ltd., check out: Exploring XTL Biopharmaceuticals Ltd. (XTLB) Investor Profile: Who’s Buying and Why?

XTL Biopharmaceuticals Ltd. (XTLB) Vision Statement of

A vision statement outlines a company's aspirations for the future. While I don't have direct access to XTL Biopharmaceuticals' official vision statement as of April 2025, understanding their activities and goals can help infer their likely vision. XTL Biopharmaceuticals Ltd. (XTLB) is a pharmaceutical company dedicated to the acquisition, development, and commercialization of pharmaceutical products for the treatment of autoimmune diseases and infectious diseases.

Given this focus, a potential vision statement could revolve around:

Leading in Innovative Therapies

This aspect of the vision could focus on pioneering new treatments and improving existing ones. For example, if XTL Biopharmaceuticals has a drug in Phase 2 clinical trials, the vision could include successfully bringing that drug to market within the next 5 years, impacting a specific patient population. The vision might emphasize a commitment to cutting-edge research and development, reflected in a substantial annual investment in R&D. As of the fiscal year 2024, many pharmaceutical companies invested heavily in research and development; for instance, some companies allocated over 20% of their revenue to R&D to remain competitive and drive innovation. This level of investment indicates a strong emphasis on future growth through novel therapies.

Improving Patient Outcomes

This part of the vision would center on the tangible benefits to patients. It could include specific, measurable goals such as:

• Reducing the severity of symptoms in autoimmune diseases by 30% within 3 years.
• Decreasing the mortality rate of specific infectious diseases by 15% over 5 years.
• Enhancing the quality of life for patients, measured by standardized patient-reported outcome measures.

Such objectives align with the broader healthcare industry's shift toward patient-centric care, where outcomes are not just about survival but also about well-being and daily functionality. By setting concrete targets, XTL Biopharmaceuticals can demonstrate its dedication to making a real difference in patients' lives.

Expanding Global Reach

This element of the vision might target geographic expansion and partnerships. For example, XTL Biopharmaceuticals could aim to establish a commercial presence in key international markets like Europe or Asia within the next 7 years. This expansion could involve strategic alliances with local distributors or other pharmaceutical companies to navigate regulatory hurdles and market access challenges. The goal is to make their therapies available to a wider global population, thereby increasing their impact and revenue streams. In 2024, many companies saw significant revenue growth by expanding into new geographic markets, with some reporting a 20-25% increase in international sales. Here is a link with more information about the company: Breaking Down XTL Biopharmaceuticals Ltd. (XTLB) Financial Health: Key Insights for Investors

XTL Biopharmaceuticals Ltd. (XTLB) Core Values of

While specific details regarding XTL Biopharmaceuticals Ltd.'s (XTLB) mission statement, vision, and core values as of April 2025 are not available in the provided search results, core values generally represent the guiding principles that define an organization's culture and priorities. These values influence a company's actions, decisions, and relationships with stakeholders.

To illustrate how a company in the biopharmaceutical sector might articulate its core values, consider the following examples, keeping in mind that these are not specific to XTL Biopharmaceuticals Ltd. but are provided for illustrative purposes:

Innovation:

A commitment to pioneering new scientific discoveries and translating them into innovative therapies that address unmet medical needs. For instance, a company might invest 15% of its annual revenue in research and development, leading to the discovery of three novel drug candidates in the past year.

Patient-Centricity:

Prioritizing the well-being of patients by developing safe, effective, and accessible treatments. This could involve conducting rigorous clinical trials with diverse patient populations and establishing patient support programs that provide education and resources to improve treatment adherence and quality of life. For example, a company might allocate $2 million annually to patient assistance programs, benefiting over 5,000 patients.

Integrity:

Upholding the highest ethical standards in all aspects of business, including research, manufacturing, and marketing. This includes transparency in data reporting, compliance with regulatory requirements, and a commitment to responsible corporate citizenship. For instance, a company might implement a comprehensive ethics training program for all employees and maintain a zero-tolerance policy for misconduct.

Collaboration:

Fostering strong partnerships with researchers, healthcare providers, and other stakeholders to advance scientific knowledge and improve patient outcomes. This could involve collaborating with academic institutions on research projects, partnering with pharmaceutical companies to develop combination therapies, and engaging with patient advocacy groups to understand their needs and priorities. For example, a company might have 10 active research collaborations with leading universities and research institutions, resulting in five co-authored publications in peer-reviewed journals.

Excellence:

Striving for excellence in all endeavors, from scientific research to manufacturing and commercial operations. This includes investing in state-of-the-art facilities, attracting and retaining top talent, and continuously improving processes to enhance efficiency and quality. For instance, a company might invest $5 million in upgrading its manufacturing facilities to meet the highest quality standards and achieve a 99.9% lot release rate.

These values are crucial for building trust with stakeholders, attracting investors, and driving long-term success in the competitive biopharmaceutical industry.

To gain more insights into the company, check this link: Exploring XTL Biopharmaceuticals Ltd. (XTLB) Investor Profile: Who’s Buying and Why?